Table III.
Mean Changes From Baseline to End Point in Blood Pressure (BP) and LDL‐C Parameters and Mean Dose of Single‐Pill Amlodipine/Atorvastatin at End Point by Cardiovascular Risk Group and All Patients Combined
| Cardiovascular Risk Group | ||||
|---|---|---|---|---|
| Group I | Group II | Group III | Total | |
| Change in BP parameters* | ||||
| Systolic BP (mm Hg) (mean ± SD) | −17.8±12.6 | −17.8±12.4 | −16.4±12.9 | −17.1±12.7 |
| Number | 163 | 468 | 576 | 1207 |
| Diastolic BP (mm Hg) (mean ± SD) | −10.7±7.9 | −10.0±7.6 | −9.0±8.2 | −9.6±8.0 |
| Number | 163 | 468 | 576 | 1207 |
| Mean dose of amlodipine component (mg)* | 7.1 | 6.7 | 7.4 | 7.1 |
| Number | 163 | 468 | 577 | 1208 |
| Change in lipid parameters** | ||||
| LDL‐C (%) (mean ± SD) | −43.7±13.2 | −37.6±14.2 | −27.5±19.1 | −32.7±17.9 |
| Number | 67 | 281 | 402 | 750 |
| Mean dose of atorvastatin component (mg)** | 25.5 | 24.1 | 29.7 | 27.2 |
| Number | 67 | 281 | 403 | 751 |
| LDL‐C=low‐density lipoprotein cholesterol; *all patients; **patients with uncontrolled LDL‐C at baseline | ||||